Pearls From the Pros on IBD Management

1.25 CME
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Patient IBD Graphic


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by educational grants from AbbVie Inc., Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.

Activity Description

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the 2 main subtypes, is a chronic relapsing condition characterized by an overly active immune response to the gut enteric flora—resulting in bowel inflammation and ulceration. Despite the increasing prevalence of disease, clinicians receive inadequate education regarding the diagnosis, classification, and management of patients with IBD. Newer pharmacotherapies may offer additional benefit to patients. In this podcast series, expert clinicians discuss the latest updates in the different classes of medications used to treat IBD.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to summarize recent advances regarding the use of biologics and small molecules for the management of patients with IBD as well as the implications for clinical practice.

Activity Chair

David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL


Maria T. Abreu, MD
Director, Crohn's and Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
University of Miami Miller School of Medicine
Miami, FL
Chair, International Organization For the Study of Inflammatory Bowel Disease

Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL

Millie D. Long, MD, MPH
Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC

Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2021 to December 30, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity

Activity Chair and Faculty report the following relationship(s)

Maria T. Abreu, MD
Consultant: AbbVie, Alimentiv, Arena, Bellatrix, Bristol-Myers Squibb, Cosmo Biopharma, Eli Lilly, Gilead, Intellisphere, Janssen, Prometheus
Speakers Bureau: Alimentiv, Arena, Intellisphere, Janssen, Takeda
Independent Research Contractor Details: AbbVie, Genentech, Pfizer, Prometheus, Takeda

Stephen B. Hanauer, MD
Consultant: AbbVie, Allergan, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres, Takeda, TiGenix, UCB, VHsquared
Independent Research Contractor Details: AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB
Speakers Bureau: AbbVie, American Recent, Bristol-Myers Squibb, Janssen, Pfizer, Takeda

Millie D. Long, MD, MPH
Consultant: AbbVie, Bristol-Myers Squibb, Calibr, Genentech, Janssen, Lilly, Pfizer, Prometheus, Roche, Salix, Takeda, Target PharmaSolutions, Theravance, Valeant
Independent Research Contractor Details: Pfizer, Takeda

David T. Rubin, MD
Consultant: AbbVie, AltruBio, Allergan, Arena, Athos, Bellatrix, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene/Syneos, Connect Biopharma, Galen/Atlantica, Genentech/Roche, Gilead, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen, Lilly, Materia Prima, Pfizer, Prometheus, Reistone, Takeda, Techlab
Independent Research Contractor Details: Takeda

Bruce E. Sands, MD, MS
Consultant: AbbVie, Abivax, Amgen, Arena Pharmaceuticals, Artugen, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Celltrion, ClostraBio, Evommune, Galapagos, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Kaleido Biosciences, Kallyope, Lilly, Pfizer, Prometheus, Protagonist Therapeutics, Q32 Bio, Sun, Surrozen, Takeda, Target RWE, Teva, Theravance, Ventryx, Viela Bio
Independent Research Contractor Details: Arena Pharmaceuticals, Theravance
Individual Stocks & Stock Option Details: Ventryx, Vivante

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at